drugset / Trial / NCT02599792

Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656

NCT02599792

Phase 1 Completed 37 enrolled Concert Pharmaceuticals
RandomizedParallel-groupTriple-blindBasic science

Summary

Two-part study to assess CTP-656 dosed as a solid oral dosage form versus Kalydeco and multiple-ascending doses of CTP-656 dosed for 7 days.

Timeline

Start
2015-11
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ivacaftor Other / unclassified 150 mg Oral
Subject deutivacaftor Unknown 75 mg Oral
Subject deutivacaftor Unknown 150 mg Oral
Subject deutivacaftor Unknown 300 mg Oral

Indications

No indication recorded.